Agilent Technologies has introduced three new models in its Dako Omnis line of staining instruments, designed to support ...

From immunotherapy to targeted agents, learn how innovative strategies are redefining outcomes in early-stage triple-negative ...

Researchers tested more than 65,000 patients with more than 30 solid tumor types and found the rate of HER2 positivity was about 3%.

Tempus AI, Inc. TEM recently introduced xM for treatment response monitoring (TRM), a liquid biopsy assay. It is designed to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in ...

The diagnosis of a suspected lung, head, and neck cancer called NUT carcinoma should include additional testing capable of ...

The diagnosis of a suspected lung, head, and neck cancer called NUT carcinoma should include additional testing capable of detecting gene fusions that are definitive markers of the disease, according ...

Foundation Medicine today announced that it has expanded its immunohistochemistry (IHC) test offerings to include MET IHC testing.

Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to include MET IHC testing ...

On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests.

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test Guardant Health, Inc. (Nasdaq: GH ...

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif.--(BUSINESS ...